Skip to main content

Drug Interactions between kava and rotigotine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

kava rotigotine

Applies to: kava and rotigotine

GENERALLY AVOID: Coadministration with kava may diminish the therapeutic effects of levodopa and other dopamine agonists. In addition, the central nervous system depressant effects of these agents may be additively or synergistically increased when taken together. Kava reportedly possesses central antidopaminergic activity, thus it can antagonize the effects of some antiparkinson medications. Extrapyramidal adverse effects including dyskinesia and dystonic reactions have been reported in association with kava use. There has also been a case report of a patient receiving levodopa for Parkinson's disease whose frequency and duration of daily 'off' periods increased significantly within 10 days after she began taking a kava extract twice daily. She returned to her normal baseline pattern of 'on' and 'off' periods two days after discontinuing the kava.

MANAGEMENT: In general, patients should consult a healthcare provider before taking any herbal or alternative medicine. Patients receiving treatment for Parkinson's disease should preferably avoid kava, since it may worsen the condition. If kava is used, patients should be alerted to the possibility of excessive sedation and monitored for potentially diminished therapeutic response to their dopaminergic therapy.

References (3)
  1. Pepping J (1999) "Kava: Piper methysticum." Am J Health Syst Pharm, 56, p. 957-60
  2. Izzo AA, Ernst E (2001) "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs, 61, p. 2163-75
  3. Schlosky L, Raffauf C, Jendroska K, Poewe W (1995) "Kava and dopamine antagonism." J Neurol Neurosurg Psychiatry, 58, p. 639-40

Drug and food interactions

Moderate

rotigotine food

Applies to: rotigotine

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References (4)
  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer